Cinnarizine

DB00568

small molecule approved investigational

Deskripsi

First synthesized by Janssen Pharmaceuticals in 1955, cinnarizine is an anti-histaminic drug mainly used for the control of vestibular disorders and motion sickness. Cinnarizine is a specific calcium channel blocker that primarily works on the central vestibular system to interfere with the signal transmission between vestibular apparatus of the inner ear and the vomiting centre of the hypothalamus. Cinnarizine could be also viewed as a nootropic drug because of its vasorelaxating abilities (due to calcium channel blockage), which happen mostly in brain. Combination use of cinnarizine with other nootropics, such as piracetam resulted in enhanced effect of boosting brain oxygen supply.

Struktur Molekul 2D

Berat 368.524
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1413 Data
Ceritinib Cinnarizine may increase the bradycardic activities of Ceritinib.
Ivabradine Cinnarizine may increase the bradycardic activities of Ivabradine.
Ruxolitinib Ruxolitinib may increase the bradycardic activities of Cinnarizine.
Deferasirox The serum concentration of Cinnarizine can be increased when it is combined with Deferasirox.
Peginterferon alfa-2b The serum concentration of Cinnarizine can be increased when it is combined with Peginterferon alfa-2b.
Leflunomide The serum concentration of Cinnarizine can be decreased when it is combined with Leflunomide.
Teriflunomide The serum concentration of Cinnarizine can be decreased when it is combined with Teriflunomide.
Cimetidine The serum concentration of Cinnarizine can be increased when it is combined with Cimetidine.
Clopidogrel The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Cinnarizine.
Efavirenz The serum concentration of Cinnarizine can be decreased when it is combined with Efavirenz.
Melatonin The therapeutic efficacy of Cinnarizine can be decreased when used in combination with Melatonin.
Nafcillin The therapeutic efficacy of Cinnarizine can be decreased when used in combination with Nafcillin.
Nitroprusside Cinnarizine may increase the hypotensive activities of Nitroprusside.
Benzylpenicilloyl polylysine Cinnarizine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Cinnarizine.
Dantrolene The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Cinnarizine.
Lithium citrate The risk or severity of adverse effects can be increased when Cinnarizine is combined with Lithium citrate.
Lithium carbonate The risk or severity of adverse effects can be increased when Cinnarizine is combined with Lithium carbonate.
Lithium hydroxide The risk or severity of adverse effects can be increased when Cinnarizine is combined with Lithium hydroxide.
Mirabegron The serum concentration of Cinnarizine can be increased when it is combined with Mirabegron.
Boceprevir The serum concentration of Cinnarizine can be increased when it is combined with Boceprevir.
Abiraterone The serum concentration of Cinnarizine can be increased when it is combined with Abiraterone.
Cyproterone acetate The metabolism of Cinnarizine can be increased when combined with Cyproterone acetate.
Amphetamine Amphetamine may decrease the sedative activities of Cinnarizine.
Phentermine Phentermine may decrease the sedative activities of Cinnarizine.
Pseudoephedrine Pseudoephedrine may decrease the sedative activities of Cinnarizine.
Benzphetamine Benzphetamine may decrease the sedative activities of Cinnarizine.
Diethylpropion Diethylpropion may decrease the sedative activities of Cinnarizine.
Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Cinnarizine.
Mephentermine Mephentermine may decrease the sedative activities of Cinnarizine.
MMDA MMDA may decrease the sedative activities of Cinnarizine.
Midomafetamine Midomafetamine may decrease the sedative activities of Cinnarizine.
2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Cinnarizine.
4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Cinnarizine.
Tenamfetamine Tenamfetamine may decrease the sedative activities of Cinnarizine.
Chlorphentermine Chlorphentermine may decrease the sedative activities of Cinnarizine.
Methylenedioxyethamphetamine Methylenedioxyethamphetamine may decrease the sedative activities of Cinnarizine.
Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Cinnarizine.
Metamfetamine Metamfetamine may decrease the sedative activities of Cinnarizine.
Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Cinnarizine.
Ritobegron Ritobegron may decrease the sedative activities of Cinnarizine.
Mephedrone Mephedrone may decrease the sedative activities of Cinnarizine.
Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Cinnarizine.
Gepefrine Gepefrine may decrease the sedative activities of Cinnarizine.
2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Cinnarizine.
Phendimetrazine Phendimetrazine may decrease the sedative activities of Cinnarizine.
Carteolol Cinnarizine may increase the arrhythmogenic activities of Carteolol.
Metipranolol Cinnarizine may increase the arrhythmogenic activities of Metipranolol.
Xylometazoline Cinnarizine may increase the arrhythmogenic activities of Xylometazoline.
Fasudil Cinnarizine may increase the arrhythmogenic activities of Fasudil.
Tropisetron Cinnarizine may increase the arrhythmogenic activities of Tropisetron.
Spiradoline Cinnarizine may increase the arrhythmogenic activities of Spiradoline.
Tiracizine Cinnarizine may increase the arrhythmogenic activities of Tiracizine.
Ethacizine Cinnarizine may increase the arrhythmogenic activities of Ethacizine.
Hydroquinine Cinnarizine may increase the arrhythmogenic activities of Hydroquinine.
Bioallethrin Cinnarizine may increase the arrhythmogenic activities of Bioallethrin.
Fosfructose Cinnarizine may increase the arrhythmogenic activities of Fosfructose.
Hydroquinidine Cinnarizine may increase the arrhythmogenic activities of Hydroquinidine.
SOR-C13 Cinnarizine may increase the arrhythmogenic activities of SOR-C13.
Digoxin Digoxin may increase the arrhythmogenic activities of Cinnarizine.
Acetyldigitoxin Acetyldigitoxin may increase the arrhythmogenic activities of Cinnarizine.
Deslanoside Cinnarizine may increase the arrhythmogenic activities of Deslanoside.
Cymarin Cinnarizine may increase the arrhythmogenic activities of Cymarin.
Metildigoxin Cinnarizine may increase the arrhythmogenic activities of Metildigoxin.
Acetyldigoxin Cinnarizine may increase the arrhythmogenic activities of Acetyldigoxin.
Disopyramide Disopyramide may increase the arrhythmogenic activities of Cinnarizine.
Ibutilide Ibutilide may increase the arrhythmogenic activities of Cinnarizine.
Bepridil Cinnarizine may increase the arrhythmogenic activities of Bepridil.
Terodiline Cinnarizine may increase the arrhythmogenic activities of Terodiline.
Diltiazem Diltiazem may increase the arrhythmogenic activities of Cinnarizine.
Nimodipine Nimodipine may increase the arrhythmogenic activities of Cinnarizine.
Atropine Cinnarizine may increase the arrhythmogenic activities of Atropine.
Adenosine Cinnarizine may increase the arrhythmogenic activities of Adenosine.
Levosimendan Cinnarizine may increase the arrhythmogenic activities of Levosimendan.
Nifedipine Cinnarizine may increase the arrhythmogenic activities of Nifedipine.
Prenylamine Cinnarizine may increase the arrhythmogenic activities of Prenylamine.
Fluspirilene Cinnarizine may increase the arrhythmogenic activities of Fluspirilene.
Azimilide Cinnarizine may increase the arrhythmogenic activities of Azimilide.
Tedisamil Cinnarizine may increase the arrhythmogenic activities of Tedisamil.
Nilvadipine Cinnarizine may increase the arrhythmogenic activities of Nilvadipine.
Fendiline Cinnarizine may increase the arrhythmogenic activities of Fendiline.
Eperisone Cinnarizine may increase the arrhythmogenic activities of Eperisone.
Melperone Cinnarizine may increase the arrhythmogenic activities of Melperone.
Benidipine Cinnarizine may increase the arrhythmogenic activities of Benidipine.
Simendan Cinnarizine may increase the arrhythmogenic activities of Simendan.
Otilonium Cinnarizine may increase the arrhythmogenic activities of Otilonium.
Nizofenone Cinnarizine may increase the arrhythmogenic activities of Nizofenone.
Bunaftine Cinnarizine may increase the arrhythmogenic activities of Bunaftine.
Lorcainide Cinnarizine may increase the arrhythmogenic activities of Lorcainide.
Penfluridol Cinnarizine may increase the arrhythmogenic activities of Penfluridol.
Dexverapamil Cinnarizine may increase the arrhythmogenic activities of Dexverapamil.
Isradipine Isradipine may increase the arrhythmogenic activities of Cinnarizine.
Trimethadione Trimethadione may increase the arrhythmogenic activities of Cinnarizine.
Amlodipine Amlodipine may increase the arrhythmogenic activities of Cinnarizine.
Lamotrigine Lamotrigine may increase the arrhythmogenic activities of Cinnarizine.
Verapamil Cinnarizine may increase the arrhythmogenic activities of Verapamil.
Losartan Cinnarizine may increase the arrhythmogenic activities of Losartan.
Moricizine Cinnarizine may increase the arrhythmogenic activities of Moricizine.
Levomenthol Cinnarizine may increase the arrhythmogenic activities of Levomenthol.
Zonisamide Cinnarizine may increase the arrhythmogenic activities of Zonisamide.

Target Protein

Histamine H1 receptor HRH1
Voltage-dependent L-type calcium channel subunit alpha-1C CACNA1C
Voltage-dependent L-type calcium channel subunit alpha-1D CACNA1D
Voltage-dependent L-type calcium channel subunit alpha-1F CACNA1F
Voltage-dependent L-type calcium channel subunit alpha-1S CACNA1S
Voltage-dependent T-type calcium channel subunit alpha-1G CACNA1G
Voltage-dependent T-type calcium channel subunit alpha-1H CACNA1H
Voltage-dependent T-type calcium channel subunit alpha-1I CACNA1I
D(2) dopamine receptor DRD2
D(1) dopamine receptor DRD1
Muscarinic acetylcholine receptor CHRM1

Referensi & Sumber

Synthesis reference: Janssen, P.A.J.; U.S. Patent 2,882,271; April 14, 1959; assigned to Laboratoria Pharmaceutica Dr. C. Janssen, Belgium.

Contoh Produk & Brand

Produk: 0 • International brands: 7
International Brands
  • Cinazyn — Italchimici
  • Cinnageron — Streuli Pharma
  • Folcodal — Ivax
  • Sepan — Janssen-Cilag
  • Stugeron — Janssen
  • Stugeron Forte — Janssen
  • Toliman — Scharper

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul